Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
Each new vaccine is required to meet the strict standards issued by the European Medicines Agency (EMA) in order to be licensed. Creative Biolabs's primary serological assay allows our laboratory to test multiple strains of a single pathogen in combination with system and sample suitability controls to increase sensitivity and accuracy. Serological techniques commonly used for quantification include hemagglutination inhibition (HI), single radial hemolysis (SRH) and virus neutralization (VN) assays.
Virus Neutralization (VN) is a useful diagnostic and basic research analysis that enables observation of humoral immune responses to viral vaccines. Compared to HI, the VN assay identifies multiple neutralizing antibodies, while HI only detects antibodies to viral hemagglutinin, which acts by preventing red blood cell agglutination.
Single tibial hemolysis (SRH) combines the advantages of single radial diffusion (SRD) and HI testing. This technique utilizes antibody diffusion within the gel to determine antibodies that may present in the serum of the assay. Hemolysis mediated by complement and induced by antibody-antigen complexes produces an easily identifiable "hemolysis zone" whose size is proportional to the concentration of anti-influenza antibodies present in serum.
For more details, please feel free to contact us for project quotations and more detailed information.
References
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
